WO2008035001A3 - Composition destinee au traitement de la sclerose laterale amyotrophique - Google Patents
Composition destinee au traitement de la sclerose laterale amyotrophique Download PDFInfo
- Publication number
- WO2008035001A3 WO2008035001A3 PCT/FR2007/051947 FR2007051947W WO2008035001A3 WO 2008035001 A3 WO2008035001 A3 WO 2008035001A3 FR 2007051947 W FR2007051947 W FR 2007051947W WO 2008035001 A3 WO2008035001 A3 WO 2008035001A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- lateral sclerosis
- amyotrophic lateral
- treatment
- conjugate
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 3
- 108010039918 Polylysine Proteins 0.000 abstract 2
- 229920000656 polylysine Polymers 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002663272A CA2663272A1 (fr) | 2006-09-18 | 2007-09-17 | Composition destinee au traitement de la sclerose laterale amyotrophique |
US12/441,808 US20090318384A1 (en) | 2006-09-18 | 2007-09-17 | Composition intended for the treatment of amyotrophic lateral sclerosis |
EP07823842A EP2063880A2 (fr) | 2006-09-18 | 2007-09-17 | Composition destinee au traitement de la sclerose laterale amyotrophique |
JP2009527873A JP2010503645A (ja) | 2006-09-18 | 2007-09-17 | 筋萎縮性側索硬化症の治療のための合剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0653789A FR2905868B1 (fr) | 2006-09-18 | 2006-09-18 | Composition destinee au traitement de la sclerose laterale amyotrophique |
FR0653789 | 2006-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008035001A2 WO2008035001A2 (fr) | 2008-03-27 |
WO2008035001A3 true WO2008035001A3 (fr) | 2008-05-22 |
Family
ID=37907089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/051947 WO2008035001A2 (fr) | 2006-09-18 | 2007-09-17 | Composition destinee au traitement de la sclerose laterale amyotrophique |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090318384A1 (fr) |
EP (1) | EP2063880A2 (fr) |
JP (1) | JP2010503645A (fr) |
CA (1) | CA2663272A1 (fr) |
FR (1) | FR2905868B1 (fr) |
WO (1) | WO2008035001A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3072513A1 (fr) * | 2015-03-26 | 2016-09-28 | Medday | Biotin pour le traitement de la sclérose latérale amyotrophique |
FR3048616B1 (fr) * | 2016-03-14 | 2018-04-06 | Polyneuros | Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique |
FR3066393B1 (fr) * | 2017-05-16 | 2019-07-19 | Polyneuros | Principe actif constitue par un melange de composes poly-lysine et utilisation dans la prevention des avc et le traitement de la phase inflammatoire post-avc |
FR3122573B1 (fr) * | 2021-05-10 | 2024-03-29 | Hydro Fill Tech | Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine |
FR3122571B1 (fr) * | 2021-05-10 | 2023-05-12 | Hydro Fill Tech | Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2727117A1 (fr) * | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
WO2006125930A1 (fr) * | 2005-05-27 | 2006-11-30 | Gemac | Composition destinee au traitement de la sclerose en plaques |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5788962A (en) * | 1995-01-17 | 1998-08-04 | The Curators Of The University Of Missouri | DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures |
-
2006
- 2006-09-18 FR FR0653789A patent/FR2905868B1/fr not_active Expired - Fee Related
-
2007
- 2007-09-17 CA CA002663272A patent/CA2663272A1/fr not_active Abandoned
- 2007-09-17 WO PCT/FR2007/051947 patent/WO2008035001A2/fr active Application Filing
- 2007-09-17 US US12/441,808 patent/US20090318384A1/en not_active Abandoned
- 2007-09-17 JP JP2009527873A patent/JP2010503645A/ja active Pending
- 2007-09-17 EP EP07823842A patent/EP2063880A2/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2727117A1 (fr) * | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
WO1996015810A1 (fr) * | 1994-11-18 | 1996-05-30 | Michel Geffard | Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine |
WO2006125930A1 (fr) * | 2005-05-27 | 2006-11-30 | Gemac | Composition destinee au traitement de la sclerose en plaques |
FR2886153A1 (fr) * | 2005-05-27 | 2006-12-01 | Gemac Sa | Composition destinee au traitement de la sclerose en plaques |
Non-Patent Citations (1)
Title |
---|
JACKSON M ET AL: "THERAPEUTIC DEVELOPMENTS IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 11, no. 10, 1 October 2002 (2002-10-01), pages 1343 - 1364, XP008035103, ISSN: 1354-3784 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008035001A2 (fr) | 2008-03-27 |
FR2905868B1 (fr) | 2012-12-21 |
CA2663272A1 (fr) | 2008-03-27 |
FR2905868A1 (fr) | 2008-03-21 |
JP2010503645A (ja) | 2010-02-04 |
US20090318384A1 (en) | 2009-12-24 |
EP2063880A2 (fr) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007146965A3 (fr) | Composés destinés au traitement d'une maladie périodontale | |
WO2007095316A3 (fr) | Compositions et procédés pour formulations à base d'oligonucléotides | |
EP1987141B8 (fr) | Compositions de traitement des maladies médiées par le collagène | |
WO2010127099A3 (fr) | Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation | |
MX2012003555A (es) | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. | |
WO2006093348A3 (fr) | Procede et composition destines au traitement des maladies vasculaires peripheriques | |
EP1991515A4 (fr) | 1,3-propanediol bio-derive et ses esters conjugues en tant que solvants naturels et non irritants pour des concentres parfumes d'extraits derives de la biomasse, et des huiles | |
IL223477A (en) | Pharmaceutical preparation containing modified enzyme uricase | |
WO2008084495A3 (fr) | Nouvelle composition agricole | |
WO2008115469A3 (fr) | Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires | |
WO2009129246A3 (fr) | Compositions et leurs procédés de préparation et d'utilisation | |
WO2008070129A3 (fr) | Compositions et procédés pour le traitement de maladie inflammatoire | |
WO2005091853A3 (fr) | Procedes et compositions pour traiter des pathologies associees a l'il-13 | |
WO2007084857A3 (fr) | Procédés et compositions de traitement de troubles prolifératifs cellulaires | |
WO2008061724A3 (fr) | Compositions innovantes | |
WO2008070268A3 (fr) | Compositions pharmaceutiques | |
WO2007138466A3 (fr) | Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol | |
WO2006105538A3 (fr) | Methodes et compositions de traitement de pathologies afferentes a l'il-21 | |
WO2009141541A3 (fr) | Utilisation d' inhibiteurs de kif13a et d ' ap-1 pour inhiber la melanogenese | |
EP2139460A4 (fr) | Compositions et procédés permettant le diagnostic, le traitement et la prévention de la sclérose latérale amyotrophique et des maladies neurologiques apparentées | |
WO2007100561A3 (fr) | Utilisation de dha et d'ara pour la preparation d'une composition destinee a la prevention ou au traitement de l'obesite | |
WO2010072787A3 (fr) | Composition et méthode de traitement d'états pathologiques cutanés | |
WO2009009417A3 (fr) | Compositions pharmaceutiques et procédés pour prévenir, traiter ou inhiber des maladies, des troubles ou des affections inflammatoires cutanés et des maladies, des troubles ou des affections associés à un appauvrissement en collagène | |
WO2008035001A3 (fr) | Composition destinee au traitement de la sclerose laterale amyotrophique | |
WO2010012386A3 (fr) | Méthode de traitement de dents hypersensibles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07823842 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2009527873 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2663272 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007823842 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12441808 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |